MEDIVATION INC's ticker is MDVN and the CUSIP is 58501N101. A total of 188 filers reported holding MEDIVATION INC in Q2 2013. The put-call ratio across all filers is 0.41 and the average weighting 0.6%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2016 | $6,727,000 | +29.8% | 111,560 | -1.0% | 0.01% | +50.0% |
| Q1 2016 | $5,181,000 | -36.6% | 112,670 | -33.3% | 0.00% | -42.9% |
| Q4 2015 | $8,171,000 | +12.3% | 169,022 | -1.3% | 0.01% | +16.7% |
| Q3 2015 | $7,275,000 | -90.1% | 171,166 | -73.5% | 0.01% | -90.2% |
| Q2 2015 | $73,831,000 | -4.4% | 646,508 | +8.0% | 0.06% | -3.2% |
| Q1 2015 | $77,240,000 | +960.3% | 598,438 | +718.3% | 0.06% | +950.0% |
| Q4 2014 | $7,285,000 | -13.7% | 73,132 | -14.3% | 0.01% | -14.3% |
| Q3 2014 | $8,438,000 | +14.6% | 85,348 | -10.6% | 0.01% | +16.7% |
| Q2 2014 | $7,362,000 | +19.9% | 95,508 | +0.1% | 0.01% | +20.0% |
| Q1 2014 | $6,141,000 | +32.4% | 95,409 | +31.3% | 0.01% | +25.0% |
| Q4 2013 | $4,637,000 | -67.6% | 72,651 | -69.5% | 0.00% | -71.4% |
| Q3 2013 | $14,295,000 | +301.2% | 238,485 | +229.3% | 0.01% | +250.0% |
| Q2 2013 | $3,563,000 | – | 72,419 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Knoll Capital Management, LLC | 2,484,101 | $158,535,000 | 79.84% |
| Cormorant Asset Management, LP | 546,900 | $34,903,000 | 10.13% |
| BB BIOTECH AG | 1,479,706 | $94,435,000 | 5.04% |
| PFM Health Sciences, LP | 2,719,859 | $173,581,000 | 3.49% |
| Partner Investment Management, L.P. | 219,981 | $14,039,000 | 3.19% |
| Orbimed Advisors | 3,123,500 | $199,342,000 | 2.93% |
| Antipodean Advisors LLC | 525,000 | $33,506,000 | 2.90% |
| Eventide Asset Management | 134,800 | $8,603,000 | 2.65% |
| Bain Capital Public Equity Management, LLC | 1,428,117 | $91,142,000 | 2.58% |
| BENNETT LAWRENCE MANAGEMENT L L C/NY | 257,055 | $16,405,000 | 2.52% |